基于二代测序的卵巢癌同源重组缺陷检测分析
该研究纳入182例卵巢癌患者,采用二代测序检测BRCA1/2突变、HRD评分、MSI和TMB,并分析其与临床病理特征的相关性。结果显示HRD阳性率为65.38%,HGSC的HRD阳性率显著高于其他亚型,BRCA突变率为36.81%,TMB-H与HRD阳性显著相关。
要点
- 卵巢癌总体HRD阳性率65.38%,HGSC中达75.97%。
- BRCA突变率36.81%,胚系突变占21.98%。
- HRD阳性患者中43.70%为BRCA野生型但HRD评分阳性。
核心结论
- NGS可全面评估卵巢癌HRD状态,HGSC中HRD阳性率较高。
- 相当比例非BRCA突变患者存在基因组不稳定性,可能从PARPi治疗中获益。
- HRD状态与TMB-H显著相关,为联合免疫治疗提供探索方向。
研究设计与样本
- 研究纳入2021年1月至2025年8月行HRD检测的卵巢癌患者182例。
- 采用NGS检测BRCA1/2等基因胚系与体细胞突变、HRD评分、MSI及TMB。
- 采用免疫组化检测错配修复蛋白和p53表达。
主要发现
- HRD阳性率为65.38%(119/182),HRD评分阳性率为53.30%(97/182)。
- HGSC占84.62%(154/182),其HRD阳性率75.97%(117/154)显著高于其他亚型7.14%(2/28),P<0.001。
- BRCA1/2突变率为36.81%(67/182),胚系BRCA1/2突变占21.98%(40/182)。
- HRD阳性患者中56.30%携带BRCA突变,81.51%为HRD评分阳性,43.70%为BRCA野生型但HRD评分阳性。
- RAD51D突变率最高为12.64%(23/182);p53 IHC与TP53突变符合率95.60%(174/182),HGSC中为96.10%(148/154)。
关键数值与推荐
- HRD阳性定义为存在BRCA1/2致病/可能致病突变和/或HRD评分阳性。
- 167例中仅1例(0.60%)为MSI-H且TMB-H,该例伴BRCA2突变且HRD评分阳性。
- TMB-H状态与HRD阳性显著相关(P<0.05),MSI状态与HRD无显著关联(P>0.05)。
临床怎么用
- 对卵巢癌患者行NGS检测可同时评估BRCA突变、HRD评分、MSI和TMB。
- HRD阳性尤其HGSC患者可能从PARPi治疗中获益,非BRCA突变但HRD评分阳性者亦需关注。
- TMB-H与HRD阳性的相关性提示可探索PARPi联合免疫治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To comprehensively evaluate homologous recombination deficiency (HRD) status via next-generation sequencing (NGS) in ovarian cancer patients and analyze its correlations with clinicopathological features, microsatellite instability (MSI), and tumor mutational burden (TMB), thereby providing evidence for genetic risk assessment, PARP inhibitor (PARPi)-targeted therapy, and prognostic management. Methods: A total of 182 ovarian cancer patients who underwent HRD testing in our department between January 2021 and August 2025 were enrolled. NGS was employed to detect germline and somatic mutations in BRCA1/2 and other genes, HRD scores, MSI, and TMB. HRD positivity was defined as the presence of a BRCA1/2 pathogenic/likely pathogenic mutation and/or a positive HRD score. Immunohistochemistry (IHC) was used to assess the expression of mismatch repair (MMR) protein and p53. Results: The overall HRD-positive rate was 65.38% (119/182), with an HRD score-positive rate of 53.30%. High-grade serous carcinoma (HGSC) constituted 84.62% (154/182) of cases and exhibited a significantly higher HRD-positive rate than those of other rare pathological subtypes [75.97% (117/154) vs. 7.14% (2/28), P<0.001]. The BRCA mutation rate was 36.81% (67/182), with germline BRCA mutations accounting for 21.98% (40/182). Within the 119 HRD-positive patients, 56.30% harbored a BRCA mutation, 81.51% were HRD score-positive, and 43.70% were BRCA wild-type but HRD score-positive. Among other homologous recombination repair (HRR) genes, RAD51D had the highest mutation rate (12.64%, 23/182). A high concordance rate of 95.60% (174/182) was observed between p53 IHC results and TP53 mutational status, which reached 96.10% (148/154) in HGSC patients. In 167 patients, only one patient (0.60%) exhibited both MSI-high (H) and TMB-H, carrying a BRCA2 mutation and was HRD score-positive. TMB-H status was significantly associated with HRD positivity (P<0.05), whereas no significant correlation was found between MSI status and HRD (P>0.05). Conclusions: NGS enables a comprehensive and integrated assessment of HRD status in ovarian cancer. Our cohort revealed a high HRD-positive rate, particularly in HGSC. A substantial proportion of patients without BRCA mutations exhibited genomic instability, suggesting potential benefit from PARPi therapy. The correlation between HRD status and TMB features provides a rationale for exploring combination immunotherapy strategies. 目的: 通过二代测序(NGS)技术评估卵巢癌患者的同源重组修复缺陷(HRD)状态,并分析其与临床病理特征、微卫星不稳定性(MSI)及肿瘤突变负荷(TMB)的相关性,为卵巢癌的遗传风险评估、PARP抑制剂(PARPi)精准治疗及预后管理提供依据。 方法: 收集2021年1月至2025年8月于中南大学湘雅二医院行HRD检测的卵巢癌患者182例。通过NGS技术检测乳腺癌相关基因(BRCA)1/2等基因的胚系与体细胞突变、HRD评分、MSI及TMB。HRD阳性定义为存在BRCA1/2致病/可能致病突变和/或HRD评分阳性。采用免疫组织化学(IHC)技术检测错配修复蛋白和p53的表达。 结果: 182例患者的HRD阳性率为65.38%(119/182),HRD评分阳性率为53.30%(97/182)。高级别浆液性癌(HGSC)占比达84.62%(154/182),其HRD阳性率(75.97%,117/154)显著高于其他少见病理亚型(7.14%,2/28,P<0.000 1)。BRCA1/2基因突变率为36.81%(67/182),其中胚系BRCA1/2突变达21.98%(40/182)。在119例HRD阳性患者中,56.30%(67例)携带BRCA1/2基因突变,81.51%(97例)的患者HRD评分阳性,43.70%(52例)的患者BRCA1/2野生型但HRD评分阳性。其他同源重组修复(HRR)基因突变率最高的是RAD51D(12.64%,23/182)。p53的IHC结果和TP53基因突变的符合率为95.60%(174/182),其中HGSC患者的符合率达96.10%(148/154)。167例患者中,仅1例(0.60%)表现为高度微卫星不稳定(MSI-H)且肿瘤突变负荷高(TMB-H),伴有BRCA2体细胞突变及HRD评分阳性。TMB-H状态与HRD阳性呈显著相关(P<0.05),而MSI状态与HRD无显著关联(P>0.05)。 结论: NGS技术可全面、整合地评估卵巢癌患者的HRD状态。尤其在HGSC队列中HRD阳性率较高;相当比例的非BRCA1/2突变患者存在基因组不稳定性,提示其可能从PARPi治疗中获益。HRD状态与TMB特征存在相关性,为联合免疫治疗提供了探索方向。.
引用
- Li NM, Cheng HP, Zhou P, et al. [Analysis of homologous recombination deficiency testing in ovarian cancer based on next-generation sequencing]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42477931. doi:10.3760/cma.j.cn112152-20251013-00505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。